NBC Los Angeles4d
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...
Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...
Novo Nordisk shares post the biggest monthly decline since 2002
Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...
Novo Nordisk’s Worst Month Since 2002 Shows Growth Concerns
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Trillion-euro dream fades for slimmed-down Novo Nordisk
Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has ...
1 Growth Stock Down 40% to Buy and Hold Forever
And speaking of dividends, Novo Nordisk pays one, and it has increased its annual dividend per share by almost 284% in the ...
The Motley Fool6d
Is Novo Nordisk Stock a Buy?
Indeed, the stakes are high. Novo Nordisk recently suffered a setback with CagriSema, its next-generation injectable drug in testing to treat both obesity and type 2 diabetes. The drug hit its ...